Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Abstract

Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib. (ClinicalTrials.gov number, NCT00322452.)

Keywords

GefitinibMedicineCarboplatinHazard ratioInternal medicinePaclitaxelOncologyLung cancerClinical endpointPopulationConfidence intervalAdenocarcinomaEpidermal growth factor receptorChemotherapyCancerRandomized controlled trialCisplatin

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

The National Lung Screening Trial: Overview and Study Design

Constantine A. Gatsonis , Denise R. Aberle , Christine D. Berg +97 more

The National Lung Screening Trial (NLST) is a randomized multicenter study comparing low-dose helical computed tomography (CT) with chest radiography in the screening of older c...

2010 Radiology 1227 citations

Publication Info

Year: 2009
Type: article
Volume: 361
Issue: 10
Pages: 947-957
Citations: 8112
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

8112

OpenAlex

Cite This

APA Style

                            
                                
                                    Tony Mok, 
                                
                                    Yi‐Long Wu, 
                                
                                    Sumitra Thongprasert
                                
                                et al.
                            
                            (2009). 
                            Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. 
                            New England Journal of Medicine
                            , 361
                            (10)
                            , 947-957.
                            https://doi.org/10.1056/nejmoa0810699
                        

Identifiers

DOI: 10.1056/nejmoa0810699